4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Yahoo Finance
Updated Sep 1, 2026
Upgrade to a paid plan to see AI rating history on the chart.
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicin…
CAMBRIDGE, Mass., August 30, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the Europea…
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Frida…
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market val…
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified…
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Not investment advice. Past performance does not guarantee future results. Full disclaimer